Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3635979 A
Publication typeGrant
Publication dateJan 18, 1972
Filing dateSep 29, 1969
Priority dateSep 29, 1969
Also published asUS3663706
Publication numberUS 3635979 A, US 3635979A, US-A-3635979, US3635979 A, US3635979A
InventorsHans-Jurgen E Hess
Original AssigneePfizer
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Certain 6- and/or 7-alkoxy-substituted-2 4-bis(disubstituted amino) quinazolines
US 3635979 A
Abstract  available in
Images(19)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent 73cc 3,635,979 CERTAIN 6- AND/OR 7-ALKOXY-SUBSTITUTED- 2,4-BIS(DISUBSTITUTED AMINO) QUINAZOLINES l-Ians-Jurgen E. Hess, Groton, Conn., assignor to Pfizer Inc., New York, N.Y.

No Drawing. Application Dec. 13, 1967, Ser. No. 690,101, now Patent No. 3,511,836, dated May 12, 1970, which is a continuation-in-part of application Ser. No. 555,704, June 7, 1966, which is a continuation-in-part of application Ser. No. 469,879, Aug. 6, 1965. Divided and this application Sept. 29, 1969, Ser. No. 871,172

Int. Cl. C07d 51/48 U.S. Cl. 260256.4 Q 1 Claim ABSTRACT OF THE DISCLOSURE Novel 2,4-diaminoquinazolines and acid addition salts thereof, their preparation, and their use as hypotensive agents.

CROSS REFERENCE TO RELATED APPLICATIONS This application is a division of application Serial No. 690,101 filed December 13, 1967 now U.S. Pat. No. 3,511,836, which, in turn, is a continuation-in-part of application Ser. No. 555,704 filed June 7, 1966 and now abandoned which, in turn, is a continuation-impart of application Ser. No. 469,879 filed August 6, 1965 and now abandoned.

BACKGROUND OF THE INVENTION This invention relates to new and useful compounds which are valuable therapeutic agents. More particularly, it is the object of this invention to provide new and useful chemotherapeutic agents valuable in reducing blood pressure in hypertensive subiects.

SUMMARY OF THE INVENTION In accordance with the present invention, compounds found to have valuable hypotensive properties are those of the formulae:

R,, R R and R are each selected from hydrogen, alkyl having from 1 to 5 carbon atoms, alkenyl having from 3 to 5 carbon atoms, hydroxyalkyl having from 2 to 5 carbon atoms, phenyl, benzyl, phenylethyl, Z-furfuryl and cycloalkyl where alkyl has from 3 to 8 carbon atoms;

Z is selected from morpholino, l-azacycloheptyl, l-azacyclooctyl and acetylamino of the formula:

where R is hydrogen, acetyl, alkyl having from 1 to 5 carbon atoms and alkenyl having from 3 to 5 carbon atoms; and

3,635,979 Patented Jan. 18, 1972 piperazino of the formula:

where Y is hydrogen, alkyl having from 1 to 5 carbon atoms, hydroxyalkyl where alkyl has from 2 to 5 carbon atoms, alkanoyl having from 2 to 7 carbon atoms, allyl, propargyl, Z-methylallyl, phenyl, benzyl, 'benzoyl, halobenzoyl and halophenyl where halo is chloro or bromo, trifiuoromethyl, methoxyphenyl, methylphenyl, methylbenzoyl, trifiuoromethylbenzoyl, furoyl, benzofuroyl, thenoyl, pyridinecarboriyl, 3,4,5 trimethoxybenzoyl, carboxylic acid alkyl ester where alkyl has from 1 to 6 carbon atoms, carboxylic acid alkenyl ester where alkenyl has from 3 to 6 carbon atoms; and

piperidino of the formula:

Included in the compounds of this invention are 2-dimethylamino-4-amino-6,7-dimethoxyquinazoline,

2-[4-(2-furoyl)-1-piperazine-l-yl]-4-amino-6,7-

dimethoxyquinazoline,

2-(4-allyl-1-piperaziny1)-4-amino-6,7-dimethoxyquinazoline,

2-[4-(2-methylallyl) -l-piperazinyl]-4-amino-6,7-

dimethoxyquinazoline, and

2-(4 -benzoyll-piperazinyl) -4-amino-6,7-dimethoxyquinazoline.

Of the preceding compounds, 2-dimethylamino-4- amino-6,7-dimethoxyquinazoline dihydrochloride has been tested and reported by I. D. Thayer et al. in Antibiotics and Chemotherapy, vol. II, No. 9, September 1952, p. 463-466, as an antibacterial agent and found to have a slight order of activity. Furthermore, U.S. Pat. No. 2,945,859, issued on July 19, 1960, to George H. Hitchings et al., discloses 2,4-diamino-6,7 -.dimethylquinazoline as an antibacterial agent. However, it is the existence of these compounds in the aforesaid prior art which necessitates my excluding them and their isomers and homologues, from the compound claims of this invention.

I have also discovered that another group of known compounds have valuable hypotensive activity. These compounds have the structure of Formula I where R and R are hydrogen or alkyl having from 1 to 3 carbon atoms; R: and R are hydrogen, alkyl having from 1 to 3 carbon atoms, at least one of R and R is dimethylaminoalkyl, diethylaminoalkyl, dipropylaminoalkyl, methylaminoalkyl, ethylaminoalkyl or propylaminoalkyl where alkyl has from 2 to 4 carbon atoms. Homologues and positional isomers of these compounds are disclosed by Chapman, Gibson and Mann, J. Chem. Soc., 895-898 (1947), and Curd, Hoggarth, Landquist and Rose, J. Chem. Soc., 1766-1773 (1948).

DETAILED DESCRIPTION OF THE INVENTION The compounds of this invention are particularly effective in reducing blood pressure in hypertensive subjects. 0n tests with renal hypertensive dogs, as little as 0.06 mg. of active ingredient per kilogram of body weight was found effective in reducing blood pressure from 180/100 to 160/100 mm. Hg. The results of these tests are shown in the examples below. These compounds are prepared by the cyclization of ureido derivatives of various aromatic acids, amides, nitriles and esters with aqueout base or acid. The ureido derivatives are obtained by reacting the aromatic compound with sodium or potassium cyanate or by reacting the aromatic acid with urea according to the procedure of F.H.S. Curd, et al in the Journal of the Chemical Society (London) 1947, p. 777.

After cyclization, the resulting 2,4-dihydroxyquinazoline is chlorinated at the 2 and 4 positions with a mixture of phosphorus pentachloride and phosphoryl chloride or with a mixture of phosphoryl chloride in N,N- dimethylaniline. The preparation of 2,4-dichloro-6,7-dimethoxyquinazoline from 4,5-dimethoxyanthranilic acid is shown in the following sequence:

onto NH1 1) NaOCEN onao -02 011.0 -ooon 2 HC1 011.0 N

H CH N N T PC15/POCl I 1 onto NH cmo N II I 0 Cl The substituents at the 5,6,7- and 8 positions of quinazoline are controlled to a great extent by the substituents on the starting aromatic acid, amide, nitrile, or ester. Exceptions such as preparing a S-aminoquinazoline by reducing S-nitroquinazoline prepared from 6- nitroanthranilic acid are obvious to one skilled in the art. Typical 2,4-dichloroquinazolines, obtained by cyclization and chlorination, and their starting compounds are given in Table I.

4,5-di-n-propylanthranilic acid 6,7-di-n-propyl- The process employed for preparing the novel compounds of this invention involves treating the corresponding 2,4-dichloroquinazoline with the appropriate amine base. The 2-chloro-4-aminoquinazolines are prepared by reacting equimolar quantities of ammonia in tetrahydrofuran and 2,4-dichloroquinazoline. However, in ordinary practice a preferred excess of ammonia would be from one to ten moles in order to shift the reaction to completion. Higher amines and nitrogenous heterocyclic compounds are likewise reacted with the dichloro compound to yield 2-chloro-4substituted-quinazolines. The temperature at which this reaction can be conducted varies from 25 to about 200 C. for a period of from one to 48 hours. A preferred reaction temperature and time for this reaction would be about 25-60 C. for about four hours. Upon completion of reaction the product is recovered by conventional means. For instance, the solvent can be evaporated and the crude solid can be triturated with water or precipitated from dilute aqueous acid in crystalline form and subsequently recrystallized from any number of appropriate organic solvents such as methanol or dimethylformamide.

Replacement of chlorine in the 2-position of the quinazoline nucleus is accomplished by reaction of the 2- chloro-4-aminoquinazoline or 2-chloro-4-substituted quinazoline with an amino compound such as piperidine in an aqueous or an organic solvent. A molar excess of base is generally employed, while preferred organic solvents for these purposes include polar solvents like tetrahydrofuran, dioxane, dimethylacetamide, dimethylformamide, or alcohols such as methanol, ethanol, and isoamyl alcohol. The reaction mixture is heated from to 160 C. for from 1 to 65 hours in a sealed pressure bottle. A preferred time and temperature is C. and 4 hours for an alkylamine or heterocyclic compound and C. for 65 hours for ammonia in ethanol. After the reaction is complete, the solvent is evaporated and the product is recrystallized from a mixture of an organic solvent and water. For instance, methanol/water. The reaction is illustrated by the, following steps:

The well known procedures for preparing salts of basic compounds are also applicable for the compounds of this invention and are illustrated in the examples below. Such salts may be formed with both pharmaceutically-acceptable and pharmaceutically-unaccepta-ble acids. By pharmaceutically-acceptable is meant those saltforming acids which do not substantially increase the toxicity of the basic compound. The preferred salts are the acid addition salts. These salts are of particular value in therapy. They include salts of mineral acids such as hydrochloric, hydriodic, hydrobromic, phosphoric, metaphosphoric, nitric, and sulfuric acids, as well as salts of organic acids such as tartaric, acetic, citric, malic, benzoic, glycollic, gluconic, gulonic, succinic, arylsulfonic, e.g., para-toluenesulfonic acids, and the like.

The pharmaceutically-unacceptable acid addition salts, while not useful for therapy, are valuable for isolation and purification of the newly recognized biologicallyactive compounds. Furthermore, they are useful for the preparation of the pharmaceutically-acceptable salts. Of this group, the more common salts include those formed with hydrofluoric and perchloric acids. Hydrofiuoride salts are particularly useful for the preparation of the pharmaceutically-acceptable salts, e.g., the hydrochloride, by solution in hydrochloric acid and crystallization of the hydrochloride salt formed. The perchloric acid salts are useful for purification and crystallization of the new compounds.

While the procedures described above are preferred for preparing the compounds of this invention on the basis of improved yields, alternate methods may also be used. The alternate methods may be divided into eight groups for convenience:

(1) Halogenation of a substituted -3 (4)-dihydroquinazoline-4-one to yield substituted-4-haloquinazolines, followed by reaction with a nitrogen-containing compound at position 4.

(2) Thiolation of a substituted -(1H,3H)-quinazoline- 2,4-dioue with or without subsequent alkylation and reaction with a nitrogen-containing compound.

(3) Alkylation, alkanoylation, aroylation and alkoxylation of piperazine attached to position 2 or 4 of the quinazoline nucleus. 7

(4) Reaction of guanidine with 2-amino-4,5-dissubstituted benzonitriles to form substituted quinazolines.

(5) Reaction of guanidines with 2-chloro-4,5-disubstituted-benzonitriles to form Z-substituted amino-4- amino-6,7-disubstituted-quinazolines.

(6) Reaction of guanidines with 2-amidino-4,5-disubstituted-anilines to form Z-substituted-amino-4-amino-6,7- disubstituted-quinazolines.

(7) Reaction of 2-chloro-4-alkoxy-6,7-disubstitutedquinazolines with ammonia or amino compounds to form Z-substituted amino 4 amino-6,7-disubstituted-quinazolines.

(8) Reaction of 2-chloro-4-methylthio 6,7- disubstituted-quinazolines with ammonia or amino compounds to form Z-substituted amino 4 amino-6,7-disubstituted-quinazolines.

In method (1),4(3H)-quinazolin'es which are described in previously copending application Ser. No. 442,205 filed Mar. 23, 1965 now abandoned, are halogenated with reagents such as phosphorous oxychloride, phosphorous oxybromide, phosphorus trichlofide, phosphorous pentachloride, thionyl chloride or the like, to produce the corresponding 4-haloquinazoline which is then reacted with an amine or heterocyclic compound according to the procedures previously described herein. The following sequence illustrates this method:

where R R R R R "R and Z are as previously described.

In this method, a molar equivalent amount, and preferably an excess, of one of the aforementioned halogenating agents is added to the 3,4-dihydroquinazoline- 4-0ne or an acid salt such as the hydrochloride, sulfate, phosphate, hydrobromide or the like. The reagent is added slowly to the quinazoline'at room temperature and then the mixture is refluxed for from about 30 minutes to about 2 hours. The latter time is sufl'icient for samples of about 10 grams of the quinazoline. Of course, longer reflux periods are desirable for larger batches in order to insure complete reaction. The liquids are evaporated and the resulting crystalline residue is then redissolved in a dilute aqueous solution of sodium bicarbonate, sodium carbonate, sodium hydroxide or the corresponding potassium salts. The aqueous solution is extracted with a solvent such as chloroform or ethyl ether. While the specific extractant is not an essential part of the process, chloroform is preferred on the basis of convenience and safety. The combined extracts are dried with a drying agent such as sodium sulfate, potassium carbonate or the like and the solvent is evaporated to yield the quinazoline substituted with chlorine or bromine on position 4. The resulting compound is reacted with ammonia, amines or heterocyclics by any of the aforementioned methods.

An alternate procedure involving this method, consists in reacting the 4-haloquinazoline with at least a molar equivalent amount of sodium sulfide, thiourea, thioacetamide or sodium methyl mercaptan. Sodium sulfide is reacted from an aqueous solution, sodium methyl mercaptan may be reacted either from aqueous solution or alkanol solution such as methanol, ethanol, isopropanol or the like. Thiourea and thioacetamide are reacted from alkanol solution and ethanol is most convenient. The reaction of the 4-haloquinazoline with these sulfur-containing compounds is accomplished at reflux for from about 2 to 8 hours, depending on the size of the samples. The reactions proceed according to the following:

N Ra *7, R5 h where R R and Z are as previously disclosed and where Z may also be where R and R are as previously disclosed. The reaction products are allowed to precipitate from the cooled reaction mixture and may be recrystallized from such solvents as ethanol-water mixtures. The recrystallized and dried products may then be reacted with heterocyclics, ammonia or amines according to the procedures previously described for reacting the 4-haloquinazolines to obtain nitrogen substituents on position 4.

where R R R R R R and Z are as previously described.

The compounds of this invention are prepared by reacting at least a molar equivalent amount of phosphorous pentasulfide with the quinazoline-2,4-dione and preferably an excess of the pentasulfide to ensure complete reaction. While the quinazoline may be dissolved in any non-reactive solvent, the use of a pyridine solution is preferred. The pentasulfide is added to the stirred solution at room temperature and then refluxed with continual stirring. As in the previous method, the reflux time is dependent on the size of the sample. After refluxing, the solvent is removed under reduced pressure, the residue is decomposed with hot water and the solid dithione is filtered from the mixture. To the dithione is added a solvent mixture of aqueous base and an alkanol. Bases useful in this method are sodium hydroxide, potassium hydroxide, and the like. Methanol, ethanol, isopropanol and butyl alcohol are useful in this method and methanol is preferred on the basis of its low boiling point. To the solution is slowly added with stirring at least a twicemolar equivalent of an alkylating agent selected from alkyl iodides, alkyl chlorides, alkyl bromides and the corresponding benzyl halides. On the basis of their case of removal from their position as alkylmercapto derivatives of quinazoline, methyl and benzyl iodide, are preferred. The mixture is heated to the boiling point of water for about 2 hours. For large samples and for lower temperatures, the time may be extended. The mixture is cooled and the precipitated product is filtered from the mixture. The resulting 2,4-dialkylor 2,4-dibenzylmercaptoquinazoline is reacted with ammonia, amines or heterocyclic compounds according to any of the previously described processes for reacting 2,4-dichloroquinazolines, to obtain the compounds of this invention. These compounds may also be prepared by reacting the dithione directly with ammonia, amines or a heterocyclic nitrogen compound and equivalent yields of product are obtained thereby.

In method (3), compounds of the formulae:

where R R R R R and R are as previously described are reacted with alkyl chlorides and alkyl bromides where alkyl has from 1 to 5 carbon atoms, alkanoyl bromides and alkanoyl chlorides where alkanoyl has from 2 to 7 carbon atoms, benzoyl chloride, benzoyl bromide, 2-methylbenzoyl halides, 3-methylbenzoyl halides and 4- methylbenzoyl halides where halide is bromide or chloride, 2-furoyl halide and 3-furoyl halide where halide is chloride or bromide, 2-thiophenoyl halide and 3-thiophenoyl halide where halide is chloride or bromide, allyl halide and methylallyl halide where halide is bromide or chloride. In the aforesaid reaction, at least a molar equivalent amount of the halide, and preferably an excess to ensure complete reaction, is added to a solution of the quinazoline in an organic solvent such as a methyl alkyl ketone, saturated aliphalic hydrocarbon or alkanol at room temperature. The reaction mixture is stirred for at least /2 hour and up to about 5 hours, depending, of course, on the size of the sample. While higher reaction times may be used they result in noxious fumes. Lower temperatures require longer periods of time for the compounds to react. The solid product is filtered from the reaction mixture and the product may be recrystallized from such solvents as methanol, ethanol, isopropanol, methylene chloride, chloroform, or the like.

In method (4) Z-aminobenzonitriles of the formula:

Rs- GEN where R and R are as previously disclosed, are reacted with guanidines of the formulae:

where R R and Z are as previously disclosed. In this method, the benzonitrile is dissolved in an inert highboiling solvent such as dimethylformamide, dimethyl sulfoxide, ethylene glycol, or the like. A molar equivalent amount and preferably and excess of the guanidine is added and the mixture is heated at about C. for from about 4 to 15 hours.

While lower temperatures may be employed for longer periods of time, about 12 hours are preferable for 0.1 molar quantities of reactants to ensure complete reaction. After heating, the solution is concentrated in vacuo to a small volume, water is added, and the mixture is chilled. The solids which precipitate are filtered from the mixture and recrystallized from solvents such as methanol-water, and dried. The reaction is illustrated as follows:

In methods and (6), the compounds of this invention are prepared by reacting compounds of the formulae:

where R and R are as previously mentioned, with guanidines of the formula:

OIZ

wherein R R R R R R and Z are as previously mentioned and wherein R is methyl, ethyl, phenyl or benzyl.

In method (8), 2-chloro-4-alkylthio 6,7 disubstitutedquinazolines are reacted with amino compounds in refluxing alcohol to obtain Z-substituted amino-4-substituted amino 6,7 disubstituted-quinazolines. The reaction sequence is as follows:

wherein R R R R R R R and Z are as previously disclosed.

The compounds of this invention are administered to hypertensive subjects either alone or in combinations with pharmaceutically-acceptable carriers. The proportion of active ingredient to carrier is determined by the solubility and chemical nature of the compound, chosen route of administration and standard pharmaceutical practice. For example, they are administered in tablet form with such excipients as lactose, sodium citrate, calcium carbonate and dicalcium phosphate. Various disintegrants such as starch, alginic acid and certain complex silicates together with lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often used. For oral administration in capsule form, preferred materials are lactose and high molecular weight polyethylene glycols. When aqueous suspensions are desired, the essential active ingredients are combined with emulsifying and/or suspending agents. Diluents such as ethanol, propylene glycol, glycerine and various combinations of diluents are employed. For parenteral administration, solutions of the active ingredients in combination with other solutes such as glucose or saline are used. Such aqueous solutions should be suitably buttered if necessary to render them isotonic.

The dosage required to reduce blood pressure in hypertensive subjects will be determined by the nature and the extent of the hypertension. Generally, small dosages will be administered initially with a gradual increase in dosage until the optimum level is determined. It will generally be found that when the composition is administered orally, larger quantities of the active ingredient will be required to produce the same level of blood pressure reduction as produced by a smaller quantity administered parenteral'ly. In general, from about 0.02 to 200 milligrams of active ingredient per kilogram of body weight administered in single or multiple dosage units elfectively reduces blood pressure in hypertensive subjects. Tablets containing 0.5 to 50 milligrams of active ingredient are particularly useful.

The following examples are given by way of illustration and are not to be construed as limiting the invention in any way. Many variations of the invention are possible within the spirit of the invention.

EXAMPLE I 2-chloro-4-amino-6,7-dimethoxyquinazoline To 800 ml. of a solution of anhydrous ammonia in tetrahydrofuran at room temperature is added 30 g. of 2,4-dichloro-6,7-dimethoxyquinazoline [F.H.S. Curd et. al., J. Chem. Soc., p. 1759 (1948)]. The mixture is stirred for 44 hours. The precipitate (29 g., M.P. 267268 C.)

1 1 is filtered and recrystallized from methanol to yield 19 g. of 2-chloro-4-amino-6,7-dimethoxyquinazoline, M.P. 302 C. (dec.).

Analysis.-Calcd. for c H N,0 c1 (percent): C, 50.11; H, 4.20; N, 17.53; Cl, 14.79. Found (percent): C, 49.99; H, 4.27; N, 17.52; Cl, 14.82.

EXAMPLE II 2,4-diamino-6,7-dimethoxyquinazoline 242-231" C. Recrystallization from water gives a product melting at 244246 C.

EXAMPLE III 2,4-diamino-6,7-dimethoxyquinazoline dihydrochloride The dihydrochloride of 2,4-diamino-6,7-dimethoxyquinazoline is prepared by dissolving the base in hot ethanol and adding an ethanolic hydrochloric acid solution to precipitate the salt.

In the same manner, acid addition salts are prepared, in lieu of hydrochloric, acid, sulfuric, nitric, hydriodic, hydrobromic, phosphoric and metaphosphoric acids, as well as salts of organic acids such as tartaric, acetic, citric, malic, benzoic, glycollic, gluconic, gulonic, succinic, arylsulfonic, c.g., p-toluenesulfonic acids and the like.

EXAMPLE IV 2,4-di-( N,N-diphenylamino) -6,7-dimethoxyquinalozine To a pressure bottle is added 7.78 g. of 2,4-dichloro- 6,7-dimethoxyquinazoline in 100 ml. of a solution of diphenylamine in ethanol. The mixture is heated at 160 C. for 65 hours. The clear solution is evaporated to dryness and the residue is recrystallized from dimethylformamide/water to yield the product. The product is dissolved in 400 ml. of hot water. The solution is made alkaline with sodium bicarbonate and the resulting precipitate is filtered. washed with water and dried to yield 2,4-di(N,N-diphenylamino) 6,7dimethoxyquinazoline.

EXAMPLE V 2-(N,N-dibeuzylamino)-4-(N,N-diethylamino)-6,7- dimethoxyquinazoline To 800 ml. of a solution of diethylamine in tetrahydrofuran at room temperature is added g. of 2,4-dichloro-6,7-dimethoxyquinazoline. The mixture is stirred I for 48 hours. The precipitate is filtered and recrystallized from methanol. To 5 grams of the product is added a 25% solution of dibenzylamine in ethanol. The mixture is heated at 160 C. for 16 hours in a pressure bottle. The solvent is evaporated and the product is recrystallized from methanol/water.

EXAMPLE VI A number of 2,4-disubstituted-amino-6,7-dimethoxyquinazolines and their pharmaceutically-acceptable acid addition salts are prepared in the same manner as Examples III, IV and V with 2,4-dichloro-6,7-dimethoxyquinazoline and the appropriate amino compound. The products of these reactions are given in Table H.

EXAMPLE VII 2,4-dichloro-6-methoxy-7-amyloxyquinazoline To 20 grams of 4-amyloxy-5-methoxy anthranilic acid in acetic acid (100 ml.) is added a suspension of sodium cyanate (11 g.) in water (50 gml.) and stirred well. After 1 hour, 2-ureido-4-amyloxy-S-methoxy benzamide is collected, washed and recrystallized from water. Twenty grams of the product is heated with 8 N hydrochloric acid (50 ml.) on a steam bath for 1 hour. The resulting product is stirred with 35% aqueous sodium hydroxide (50 ml.) to form the sodium salt. The salt is filtered, redissolved in 500 ml. hot water and re-precipitated with acetic acid to give 2,4-dihydroxy-6-methoxy-7-amyloxyquinazoline. The product is dried and converted to 2,4- dichloro-compound by refluxing 10 grams of the dihydroxy material with 16 g. phosphorous pentachloride and 10 ml. phosphoryl chloride-for several hours. After removal of the phosphoryl chloride, the product is distilled from the flask under reduced pressure.

EXAMPLE VIII 2,4-dichloro-6-amyloxy-7-methoxyquinazoline The compound is prepared from 4-methoxy-5-amyloxyanthranilic acid according to the procedure of Example VII.

EXAMPLE IX 2,4-dichloro-6,7-diamyloxyquinazoline To 20 grams of 4,5-diamyloxyanthranilamide is acetic acid (100 cc.) is added a suspension of 11 g. sodium cyanate in 50 ml. water and stirred well. After 1 hour, 2-ureido-4,5-diamyloxybenzamide is collected, washed and recrystallized from water. Twenty grams of the product is heated with 8 N hydrochloric acid cc.) on a steam bath for 1 hour. The resulting product is stirred with 35% sodium hydroxide cc.) to form the sodium salt. The salt is filtered, redissolved in 500 cc. hot water and re-precipitated with acetic acid to give 2,4-dihydroxy- 6,7-diamyloxyquinazoline. The product is dried and converted to 2,4-dichloro-6,7-diamyloxyquinazoline by refluxing 10 grams of dihydroxy compound with 16 g. phosphorous pentachloride and 10 cc. phosphoryl chloride for six hours. After removal of the phosphoryl chloride, the product is distilled from the flask under reduced pressure.

EXAMPLE X 2,4-dichloro-6,7-diethoxyquinazoline The 2,4dichloro-6,7-diethoxyquinazoline is prepared by the procedure of Example IX starting with 4,5-diethoxyanthranilarnide, 4,5-diethoxyanthranilic acid or a lower alkyl ester such as methyl 4,5-diethoxyanthranilate.

EXAMPLE XI A series of 2,4-disubstituted amino-6,7-diamyloxyquinazolines and their pharmaccutically-acceptable acid addition salts are prepared from 2,4-dichloro-6,7-diamyloxyquinazoline by the procedures of Examples III, IV, V and IX. These compounds are listed in Table II.

EXAMPLE XII A series of 2,4-disubstituted amino-6,7-diethoxyquinazolines and their pharmaceutically-acceptable acid addition salts are prepared from 2,4-dichloro-6,7-diethoxyquinazoline according to the procedure of Examples II, IH and VI. These compounds are listed in Table II.

S-methoxyanthranilic acid such as methyl S-methoxyanthranilate.

EXAMPLE XIV 2,4-dichloro-7-methoxyquinazoline The 2,4-dichloro Q 7 methoxyquinazoline is prepared from 4 methoxyanthranilamide, 4 methoxyanthranilic 13 acid or a lower alkyl ester of the acid according to the procedure of Example VIII.

EXAMPLE XV 2,4-disubstituted-6-methoxyquinazolines and 2,4-disubstir tuted-7-methoxyquinazolines The substituted -6- and 7-methoxyquinazolines and their l4 EXAMPLE XIX 2,4-disubstituted-6-methoxy-7-amyloxyquinazoline The 2,4-disubstituted-6-methoxy-7-amyloxyquinazoline and its pharmaceutically-acceptable acid addition salts are prepared by the procedures of Examples II, III and XVII. These compounds are listed in Table II.

pared according to the procedures of Examples H, HI, XII and XIII. These compounds are listed in Table II.

EXAMPLE XVI 2,4-dichloro-6-(7)-amyloxyquinazoline The 2,4dichloro-6-amyloxyquinazoline and the 2,4-dichloro-7-amyloxyquinazoline and their pharmaceuticallyacceptable acid addition salts are prepared according to the procedure of Example VIII from S-amyloxyanthranilamide and 4-amyloxyanthranilamide, respectively, or the corresponding acids and lower alkyl esters.

EXAMPLE XVII 2,4-disub stituted-6- (7 -amyloxyquinazoline The 2,4-disubstituted-6-(7)-amyloxyquinazolines and their corresponding pharmaceutically-acceptable acid addition salts are prepared from the corresponding dichlorocompound according to the procedures of Examples II, III and XV. These compounds are listed in Table II.

EXAMPLE XVIII .2,4-dichloro-G-methoxy-7-amyloxyquinazoline The 2,4-dichloro-6-methoxy-7 arnyloxyquinazoline is prepared by the procedure of Example VIII with 4-arnyloxy-S-methoxyanthranilamide, 4 amyloxy methoxyanthranilic acid or its lower alkyl esters.

Z-amino-4-morpholino-6,7-dimethoxyquinazoline To ml. of a 25% solution of morpholine in tetrahydrofuran at room temperature is added 30 g. 2,4dichloro-6,7-dimethoxyquinazoline. The mixture is stirred for 48 hours. The precipitate is filtered and recrystallized from methanol. To 5 g. of the product is added ml. of ethanolic ammonia. The mixture is heated at C. for 16 hours in a pressure bottle. The solvent is evaporat ed and the residue is recrystallized from methanol/water.

EXAMPLE XXI The 2-amino-4-substituted 6,7 dimethoxyquinazolines and their pharmaceutically-acceptable acid addition salts are prepared from 2,4-dichloro-6,7-dimethoxyquiuazoline according to the procedures of Examples XX and III. These compounds are listed in Table III.

EXAMPLE XXH ZdimethylaminoA-morpholino-6,7-dimethoxyquinazoline 15 orated and the residue is recrystallized from methanol/ water.

EXAMPLE XXIII The 2,4-disubstituted 6,7 dimethoxyquinazolines and their pharmaceutically-acceptable acid addition salts are prepared according to the procedures of Examples III and XXII. These compounds are listed in Table III.

EXAMPLE XXIV 2-amino-4-morpholino-6-methoxy-7-amyloxyquinazoline This compound is prepared from 2,4-dichloro-6-methoxy-7-amyloxyquinanzoline according to the procedures of Examples VII and XX. The dihydrochloride salt is prepared from the base compound according to the procedure of Example III.

EXAMPLE XXV The 2-amino-4-substituted-6-methoxy 7-amyloxyquinazolines are prepared according to the procedure of Expared according to the procedure of Example III. These compounds are listed in Table III.

EXAMPLE XXV II The 2,4-disubstituted 6(7)amyloxyquinazolines and the 2-amino-4-substituted 6(7)amyloxyquinazolines are prepared according to the procedures of Examples XVI, XV and XIX. The dihydrochloride salt is prepared according to the procedure of Example III. These compounds are listed in Table III.

EXAMPLE XXVIII pounds are illustrated in Table IH.

EXAMPLE XXVI The 2-amino-4-substituted 6(7)-methoxyquinazolines and the 2,4-disubstituted 6(7)rnethoxyquinazolines are prepared according to the procedures of Examples XIII, XIV, XXIII and XXI. The dihydrochloride salt is prequinazolines To 5 grams of 2-chloro-4-amino 6,7-dimethoxyquinazoline prepared as in Example I, is added 20 grams of a 25% solution of 4-methylpiperazine in ethanol. The mixture is heated at 160 C. for 16 hours in a pressure bottle. The solvent is then evaporated and the residue is 75 recrystallized from methanol/water.

1 7 EXAMPLE XXX EXAMPLE XXXI The Z-substituted 4-amino-6,7-dimethoxyquinazolines are prepared as in Example XXIX. The dihydrochloride salt is prepared according to the procedure of Example III. These compounds are listed in Table IV.

18 amyloxyquinazoline. The dihydrochloride salts are prepared as in Example III. These compounds are listed in Table IV.

EXAMPLE XXXIV The 2,4-disubstituted 6-methoxy 7-amyloxyquinanzolines are prepared from 2,4-dichloro-6-methoxy-7-amyloxyquinazoline according to the procedure of Example XXX. The pharmaceutically-acceptable acid addition salts are prepared according to the procedure of Example III. These compounds are listed in Table IV.

EXAMPLE XXXV The 2,4-disubstituted 6(7)methoxyquinazolines are prepared from 2,4-dichloro 6-methoxyquinazoline and 2,4-dichloro-7-methoxyquinazolines according to the procedure of Example XXX. The pharmaceutically-acceptable acid addition salts are prepared according to the procedure of Example III. The compounds are listed in Table IV.

The 2,4 disubstituted 6,7 dimethoxyquinazolines where carbon 2 is substituted with a heterocyclic nitrogen compound, are prepared as in Example XXX. These 70 compounds are listed in Table IV.

EXAMPLE XXXIII The 2,4-disubstituted 6,7-diamyloxyquinazo1ines are 2-(N,N-dimethylamino)-4-amino-6,7- dimethoxyquinazoline To 5 grams of 2-chloro-4-amino-6,7-dimethoxyquinazoline, prepared according to the procedure of Example I, is added 50 ml. of a 25% solution of dimethylamine in ethanol. The mixture is heated for 16 hours at 160 prepared as in Example xxx from 2,4-dichloro-'6,7-di- 75 C. in a sealed pressure bottle. The solvent is evaporated and the residue is crystallized from methanol/water to yield the product. M.P. 219-222 C.

EXAMPLE XXXVII 2-(N,N-dimethylamino)-4-amino-6,7- dimethoxyquinazoline To grams of 2-chloro-4-amino-6,7-dimethoxyquinazoline is added 50 ml. of a 25% solution of diethylamine in ethanol. The mixture is heated for 16 hours at 160 C. in a pressure bottle. The solvent is evaporated and the residue (6.9 g.) is crystallized from methanol/water to yield 3.3 grams of product melting at 179180 C.

Analysis.-Calcd. for C H N O (percent): C, 60.85; H, 7.30; N, 20.28. Found (percent): C, 61.07; H, 7.17; N, 20.31.

EXAMPLE XXXVIII 2-(N,N-diethyla-mino) -4-amino-6,7-dimethoxquinazoline dihydrochloride The dihydrochloride is prepared by dissolving the base in hot ethanol and adding ethanolic hydrochloric acid solution to precipitate the salt. M.P. 259-260 C.

EXAMPLE XXXIX 2- (N,N liallylamino -4-amino-6,7- dimethoxyquinazoline The compound is prepared by the procedure of Example XXXVH using diallylamine in ethanol rather than diethylamine. The product melts 177-179 C. The dihydrochloride salt, prepared as in Example XXVIII, melts 227-229 C.

EXAMPLE XL 2-amino-4- N,N-dimethylamino -6,7- dimethoxyquinazoline To 80 grams of a solution of dimethylamine in tetrahydrofuran at room temperature is added 30 grams 2,4-dichloro-6,7-dimethoxyquinazoline. The mixture is stirred 48 hours. The resulting precipitate is filtered and recrystallized from methanol. To 5 grams of the product is added 100 ml. of ethanolic ammonia. This mixture is heated at 160 C. for 16 hours in a sealed pressure bottle. The solvent is evaporated and the residue is recrystallized from methanol/water.

EXAMPLE XL'I 2-amino-4-(N,N-diamylamino)-6,7- diamyloxyquinazoliue To 30 grams of 2,4-dichloro-6,7-diamyloxyquinazoline prepared as in Example IX, is added 80 grams of a 10% solution of diamylamine in tetrahydrofuran. The mixture is stirred for 48 hours. The precipitate which forms is filtered and recrystallized from methanol. To 5 grams of the product is added 100 ml. ethanolic ammonia. This mixture is heated at 160 C. for 16 hours in a sealed pressure bottle. The solvent is evaporated and the residue is recrystallized from methanol/water.

EXAMPLE XLII 2-4-di (N,Ndimethylamino) -6,7- dimethoxyquinazoline To 80 grams of a 10% solution of dimethylamine in tetrahydrofuran at room temperature is added 30 grams 2,4-dichloro-6,7-dimethoxyquinazoline. The mixture is stirred 48 hours. The resulting precipitate is filtered and recrystallized from methanol. To 5 grams of the product EXAMPLE XLIII 2,4-di(N,N-diamylamino)-6,(7)-dimethoxyquinazoline This compound is prepared with diamylamine according to the procedure of Example XLII.

EXAMPLE XLIV 2,4-di(N,N-dimethylamino)-6,(7)-methoxyquinazoline These compounds are prepared from 2,4-dichloro- 6-methoxyquinazoline (Example XIII) and 2,4-dichloro- 7-methoxyquinazoline (Example XIV) according to the procedure of Example XLII.

EXAMPLE XLV 2-methylamino-4-amino-6,7-dimethoxyquinazoline This compound is prepared by the procedure of Example XXXVII by reacting 2-chloro-4-amino-6,7- dimethoxyquinazoline with an ethanolic solution of methylamine.

EXAMPLE XLVI 2-amylamino-4-amino-6,7-dimethoxyquinazoline This compound is prepared by the procedure of Example XXXVII by reacting 2-chloro-4-amino-6,7- dimethoxyquinazoline with an ethanolic solution of amylamine.

EXAMPLE XLVII Z-N-ethylanilino-4-amino-6,7-dimethoxyquinazoline This compound is prepared by the procedure of Example XXXVII by reacting 2-chloro-4-amino-6,7- dimethoxyquinazoline with N-ethylaniline.

EXAMPLE XLVIII Z-N-methylbutylamino-4-amino-6,7-dimethoxyquinazoline This compound is prepared by the procedure of Example XXXVII by reacting 2-chloro-4-amino-6,7- dimethoxyquinazoline with N-methylbutylamine.

EXAMPLE XLIX 2-amino-4-N-methylbutylamino-6,7-dimethoxyquinazoline This compound is prepared by the procedure of Example XL by reacting N-methylbutylamine with 2,4-dichloro-6,7-dimethoxyquinazoline.

EXAMPLE L The biological activity of the compounds of this invention, particularly in regard to their effectiveness in reducing blood pressure in hypertensive subjects, is illustrated by the following tests on renal hypertensive dogs. The compounds were administered orally in capsule form. The effective dose level was that which lowered the blood pressure from 180/ to /100 mm. Hg. The activity of the compounds is shown in Table XVIII.

21 Table XVIII Compound: concentration, mg./kg. 2,4-diamino-6,7-dimethoxyquinazoline 2.50 2 methylamino 4 amino-6,7-dimethoxyquinazoline 2.50 2 ethylamino 4 amino 6,7-dimethoxyqtiinazoline 2.50 2 n propylamino 4 amino-6,7-dimethoxyquinazoline 2.50 2 n butylamino 4 amino -6,7 dimethoxyquinazoline 2.50 2 'isopropylamino 4 amino-6,7-dimethoxyquinazoline 1.25 2 dimethylamino 4 amino 6,7 dimethoxyquinazoline 0.63 2 diethylamino 4 amino-6,7-dimethoxyquinazoline 1.25 2 N methyl-(p-hydroxyethyl)amino-4-amino- 6,7-dimethoxyquinazoline 2 diallylamino 4 amino-6,7-dimethoxyquinazoline 10 2 (4 methyl 1 piperazinyl)-4-amino-6,7-dimethoxyquinazoline 2.50 2 3,6,3 trifiuoroethylamino 4 amino-6,7-dimethoxyquinazoline 2.50 2 (4 n propyl-l-piperazinyl)-4-amino-6,7-

dimethoxyquinazoline 2.5 2 (diethanolamino) 4-amino-6,7-dimethoxyquinazoline 10 2 (dimethylamino) 4 methylamino-6,7-dimethoxyquinazoline 2.50 2,4 di(diethylamino) 6,7 dimethoxyquinazoline 10 2,4 di(N,N dimethylamino)-6,7-dimethoxyquinazoline 10 EXAMPLE LI Tablets A tablet base is prepared by blending the following ingredients in the proportion by weight indicated:

Sucrose, U.S.P. 8-0.3 Tapioca starch 13.2 Magnesium stearate 6.5

Into this base there is blended sufiicient Z-dimethylamino- 4amino-6,7-dimethoxyquinazoline to provide tablets con- Magnesium stearate B 0.35

To this blend is added sufiicient 2-(4-propyl-1-piperazinyl)-4-amino-6,7-dimethoxyquinazoline to provide capsules containing 20, 100 and 250 mg. of active ingredient.

EXAMPLE LIII Injectable preparation One thousand grams of 2-methylamino-4-amino-6,7- dimethoxyquinazoline are intimately mixed and ground with 2500 grams of sodium ascorbate. The ground dry mixture is filled into vials, sterilized with ethylene oxide and the vials sterilely stoppered. For intravenous admin- 22 istration sufiicient water is added to the vials to form a solution containing 10 mg. of active ingredient per milliliter.

EXAMPLE LIV Suspension A suspension of 2-(N,N-diallylamino)-4-amino-6,7- dimethoxyquinazoline is prepared with the following composition:

Effective ingredient-31.42 g.

70% aqueous sorbitol-7 14.29 g. Glycerine, U.S.P.-185.35 g.

Gum acacia (10% solution)100.00 ml. Polyvinyl pyrrolidone0.5 g.

Water, distilled to make 1 liter.

To this suspension, various sweetening and flavoring agents may be added by choice. The suspension contains approximately 25 mg. of hypotensive agent per milliliter.

EXAMPLE LV Solution A solution of 2 dimethylamino 4 methylamino- 6,7-dimethoxyquinazoline is prepared with the following composition.

Eifective ingredient-30.22 g.

Magnesium chloride hexahydrate-l2.36 g. Monoethanolamine--8.85 ml.

Propylene glycol376 g.

Water-94 ml.

The solution has a concentration of 50 mg./m1. and is suitable for parenteral and especially for intramuscular administration.

EXAMPLE LVI The methods employed for the preparation of the compounds of the previous examples are also used to prepare compounds having substituents other than alkoxy on positions 5, 6, 7 and 8 of the quinazoline nucleus. These compounds are prepared from substituted aromatic com pounds such as those in Table XIX, followed by chlorination as described in Examples VII, VIII, IX and X. These compounds are as follows:

Table XIX Substituted 2,4-dichloroquinazolines Starting compound: substituents Methyl 5-chloroanthranilate 6-chloro- 4-chloroanthranilic acid 7-chloro- Methyl 3-bromoanthranilate S-bromo- Methyl 6-fluoroanthranilate S-fluoro- Methyl 4-fiuoroanthranilate 7-fiuoro- 4,5-dimethylanthranilamide 6,7-dimethyl- S-pentylanthranilic acid 6-pentyl Methyl 4-isopropylanthranilate 7-isopropyl- Methyl fi-chloroanthranilate S-chloro- Methyl 3-chloroanthranilate 8-chloro- Ethyl 3-fluoroanthranilate 8-fluoro- S-methylanthranilic acid 6-methyl- 6-methylan thranilic acid S-methyl- 3-methylanthranilic acid S-methyl- S-nitroanthranilic acid G-nitro- 6-nitroanthranilic acid S-nitro- B-amino-p-tolunitrile 7-methyl- 2-amino-4,S-dichlorobenzoic acid 6,7-dichloro- Z-aminopiperonylic acid 6,7-methylenedioxy- 2-amino-4,5-ethylenedioxybenzoic acid 6,7-ethylene- 2-naphthylamine-3-carboxylic dioxyacid 6,7-benzo- 4,5-dimethylanthranilic acid 6,7-dimethyl 4,5,6-trimethoxyanthranilic acid 5,6,7-trimethoxy These compounds are effective hypotensive agents whose activities are similar to those in the previous examples. In addition, compounds selected from the group having the formula:

wherein R R and Z are as previously described are also effective hypotensive agents. The compounds of this example are prepared according to the procedures of the preceding examples. They are used in the same manner with regard to dosage level and dosage form as the compounds in the previous examples. A specific example of the preparation of this type of compound is as follows:

NHz 2-dimethylamino-4-amino-6,7-benzoquinazoline mixture is heated in a sealed pressure bottle for 16 hours at 160 C. The solvent is evaporated and the product is recrystallized from methanol/water.

EXAMPLE LVII 4-(4-amino-6,7-dimethoxyquinazoline-2-yl)-piperazine-1- carboxylic acid isobutyl ester Preparation of isobutyl 1-piperazinecanboxylate.-To 11.6 grams of anhydrous piperazine in 127 ml. ethanol and 16 ml. W816i is added with stirring over a minute period, 22.6 grams 48% aqueous hydrobromic acid. The temperature rises to C. during the addition. Isobutyl chloroformate (875 grams) is then added over another 30 minute period and the resulting solution is refluxed for 1.5 hours and chilled. The piperazine dihydrobromide which crystallizes is filtered and the solution is concentrated to an oil in vacuo. The oil is taken up in water, neutralized with dilute aqueous sodium hydroxide and extracted with several portions of methylene chloride. The combined extracts are dried with sodium sulfate and the methylene chloride is evaporated to yield 9.9 grams of an oil which is distilled in vacuo, B.P. 87-90 C./ 0.3 mm. Hg pressure. The yield of colorless product is 7.17 grams or 60% of theory.

This same procedure is used to prepare 1-(2-furoyl)- piperazine, 1 allylpiperazine, 1 (2 methylallyl) piperazine, l crotonyl piperazine, propyl l piperazinecarboxylate, allyl 1 piperazinecarboxylate, and n pentyl-l-piperazinecarboxylate.

Preparation of quinazoline derivative of isobutyl 1- piperazinecarboxylate.A mixture of 7.17 grams of 2- chloro 4 amino 6,7 dimethoxyquinazoline and 11.7 grams of isobutyl 1 piperazinecarboxylate in ml. of ethanol is heated in a pressure bomb at C. for 4 hours. The reaction mixture is cooled and the solvent evaporated. The resulting residue is triturated with 300 ml. water. The insoluble material is filtered from the water and dissolved in 50 ml. methanol. The methanol is displaced with 50 ml. of ethyl acetate and the product is I precipitated and collected by filtration. The product is dissolved in warm ethanol-1 N hydrochloric acid and chilled. The crystals of the resulting hydrochloride are filtered from the solvent and dried to yield 8.1 grams of product (62% of theory) melting at 277-278 C.

Analysis-Calcd. for C1gH2704N5HC1 /2H2O (percent): C, 52.47; H, 6.72; N, 16.12; Cl, 8.15. Found (percent): C, 52.69; H, 6.86; N, 16.23; Cl, 7.86.

EXAMPLE LVIII 2-(4-allyl-l-piperazinyl)-4-amino-6,7- dimethoxyquinazoline To 18.9 grams of 2-chloro-4-amino-6,7-dimethoxyquinazoline in 280 ml. of isoamyl alcohol is added 19.9 grams of l-allylpiperazine prepared as in Example LVII. The mixture is refluxed for 20 hours, and cooled. The l-allylpiperazine hydrochloride formed is extracted with water and the organic layer is concentrated in vacuo to an oil which crystallizes when triturated with hexane. The solids are collected by filtration and dried to give 20.4 grams of product, M.P. 198-201 C.

The hydrochloride salt is prepared by redissolving the product in ethanol/1 N hydrochloric acid and chilling. The resulting crystals, when dried melt at 282-283 C.

EXAMPLE LIX 2-(4-benzylpiperidino) -4-amino-6,7-dimethoxyquinazoline To 7.17 grams of 2-chloro-4-amino 6,7-dimethoxyquinazoline in ethanol is added 10.5 grams 4-benzylpiperidine. The mixture is heated in a pressure bottle for 4 hours at 140 C. The mixture is cooled, the solvent is evaporated and the residue is redissolved in methanolchloroform (1:1). This solvent is displaced with ethyl acetate causing crystallization of product. The crystals collected weigh 6.8 grams, M.P. 260-262 C.

Analysis.Calcd. for C H O N HCl (percent): C, 63.68; H, 6.56; N, 13.50; Cl, 8.55. Found (percent): C, 63.76; H, 6.58; N, 13.72; Cl, 8.43.

EXAMPLE LX 4- (4-amino-6,7-dimethoxyquinazoline-Z-yl) -piperazine-1- carboxylicacid ethyl ester hydrochloride This compound is prepared from ethyl l-piperazinecarboxylate and 2-chloro-4-amino-6,7-dimethoxy quinazoline according to the procedure of Example LVII.

Analysis.-Calcd. for C17H2304N5HCl /2H2O (percent): C, 50.19; H, 6.19; N, 17.22; Cl, 8.71. Found (percent): C, 49.78; H, 6.15; N, 17.11; C], 8.70. M.P. 277- 278 C.

EXAMPLE LXI 4- (4-amino-6,7-dimethoxyquinazoline-2-yl) -piperazinel-carboxylic acid allyl ester hydrochloride This compound is prepared from allyl l-piperazinecarboxylate and 2-chloro-4-amino-6,7-dimethoxyquinazoline according to the procedure of Example LVII, The hydrochloride melts at 260262 C.

EXAMPLE LXII 2 [4- (p-hydroxyethyl)-piperidino] -4-amin0-6,7-dimethoxyquinazoline hydrochloride EXAMPLE LXVII The biological activity of the compounds of this invention was tested according to the procedure of Example L. The activity of the compounds is given in Table XVIII of Example L and Table XXII.

TABLE XXIL-HYPOTENSIVE ACTIVITY N 011.0 16 N R EXAMPLE LXVIII Z-diethylaminc-4-chloro-6,7-dimethoxyquinazoline A mixture of grams 2-diethylamino-6,7-dimethoxy- 4(3H)-quinazolene hydrochloride in 50 ml. of phosphorous oxychloride is refluxed for 2 hours. The liquids are evaporated to give a crystalline residue of 2-diethylamino-4-chloro 6,7 dimethoxyquinazolinc hydrochloride, M.P. 175l84 C. The product is dissolved in dilute sodium hydrogen carbonate aqueous solution and is extracted several times with chloroform. The combined chloroform extracts are dried with sodium sulfate and the solvent is evaporated to yield 7.6 grams (82% of theory) of product, M.P. 129-151 C.

Analysis.Calcd. for C H O H HCl. (percent): C, 56.86; H, 6.13; N, 14.21. Found (percent): C, 56.81; H, 6.08; N, 13.97.

EXAMPLE LXIX 2-diethylamino-4-amino-6,7-dimethoxyquinazoline The product of Example LXVIII is dissolved in ml. tetrahydrofuran and a solution of anhydrous ammonia in tetrahydrofuran is added. The mixture is stirred at room temperature for 24 hours and the resulting precipitate is collected. The product is recrystallized from isopropyl alcohol. The dried product melts at 179180 C.

EXAMPLE LXX 2-(4-allyl-1-piperazinyl)-4-aminO-6,7- dimethoxyquinazoline To 10 grams of 6,7-dimethoxy-(1H,3H)-quinazolinedione in 200 ml. pyridine is added 30 grams phosphorous pentasulfide and the mixture is refluxed with continuous stirring for 5 hours. The solvent is removed under reduced pressure and the residue is decomposed with hot water. The solid material is filtered from the mixture. The product is 6,7-dimethoxy-(1H,3H) quinazolinedithione.

To 0.1 mole of 6,7-dimethoxy-(1H,3H)-quinazolinedithione in 220 ml. 1 N potassium hydroxide solution and 100 ml. methanol, is added slowly with stirring, 0.22 mole of methyl iodide. The mixture is heated on a steam bath for 2 hours, cooled, and the resulting precipitate is filtered from the mixture. The product is 2,4-dimethylmercapto-4-amino-6,7-dimethoxyquinazoline.

To 0.1 mole of 2,4-dimethylmercapto-6,7-dimethoxyquinazoline in 200 ml. of tetrahydrofuran is added a solution of 0.1 mole of anhydrous ammonia in tetrahydrofuran. The mixture is stirred at room temperature for 18 hours and the precipitate which forms is collected and recrystallized from dimethylformamide/water to yield 2-methylmercapto-4-amino-6,7 dimethoxyquinazoline.

A mixture of 0.1 mole of 2-methylmercapto-4-amino- 6,7-dimethoxyquinazoline and 0.12 mole of l-allylpiperazine is isoamyl alcohol is heated at reflux for 13 hours. The reaction mixture is cooled, washed with water, and the organic layer is concentrated in vacuo. Hexane is slowly added to the oily residue and the solids which form are collected. The product is 2-(4-allyl-1-piper- 29 azinyl)-4-amino 6,7 dimethoxyquinazoline, M.P. 198 201 C.

EXAMPLE LXXI 2-(4-a1lyl-1-piperaziny1)-4-amino-6,7- dimethoxyquinazoline To. 0.10 mole of 2-(1-piperazinyl) 4 amino-6,7-dimethoxyquinazoline in 300 ml. of methanol at 50 C. is added with vigorous stirring 0.10 mole allyl bromide. The mixture is heated at reflux for 2 hours, cooled, and the crystalline material is filtered. Recrystallization from ethanol yields the desired product.

EXAMPLE LXXII 2- [4- (Z-furoyl) -piperazine-yl] -4-amino-6,7- dimethoxyquinazoline To 0.10 mole 2 (1 piperazinyl) 4 amino-6,7-dimethoxyquinazoline in 300 ml. methanol is added with vigorous stirring, 0.10 mole 2-furoyl chloride. After addition is complete, the mixture is stirred for 3 hours at room temperature. The solids are filtered to give the desired product, M.P. 278280 C.

EXAMPLE LXXIII EXAMPLE LXXV The 2,4-disubstituted 6,7 benzoquinazolines of formula:

are prepared from 2,4-dichloro-6,7 bengoquinaaoline,

described in Example LVI and by the procedures Examples XIX, XXII, XXIX, XXX, XXVIII and XXV. These compounds are listed in Table XXIV.

EXAMPLE LXXVI The 2,4 disubstituted 6,7 dimethoxyquinazolines of Table XXV are prepared according to the procedures of Examples I and XXXVII substituting the appropriate amine for diethylamine.

TAB LE XXV N R. l F-Z Ra N H-N\ M12 0. Ra R4 R2 R1 R1 Base 2.1161 ign ggzggzgggr ggz' 24:241 440 Where R and R are methyl, ethyl, n-propyl and ISO- Z Z Z QZ "@5531 2621264 propyl and where Z is as mdlcated in Table XXIII, are g gggzggzgggfi gh 23: 2:? gag-32g ggli g the li gg( x% i G EH: gg H icf liN 1C2 a) 2 102-104 255-256 II XXVI an ese compoun s are 1 20 2N cH(OH=) 303-504 9 i H h ted In Table XXIII. CH(CH )CH2CHCH2N(C2H)2 -187 231 233 TABLE XXIII R, or R, R2 or R4 at R, z

11- H H CH; cyclopropylamlno- H- H- CHr- CH; 4-crotonyl-1-piperaziny1- H H CH3- H- B-hydroxyplperidino- H- CH3 CzHs H 3-methoxyplperidlno- H- CzHs- C2H5 3-n-propoxypiperidino- H- n-CsH1- n-CaH1- CH5 3n-butoxypiperidino- H- H- n-C;H1 n-C H1-- S-hydroxymethylpiperldlno- CH;- H- lSO-CaH1- i50-CsH1 3-hydroxyhexylplperldino- CH; CH; CzHrr- C2Hscyclopropylaminm n-Ca 1-- a 1-- CHs- H- piperidino- CH=CCH2 Ha- CHa-- CH;- piperidino- CH2 CHCH2 CH2= CH-CHz- CH1:- CH3 4-(3-fur0y1) -1-pipera7.lnyl- CH2= OH-CHr- CH2 CH-CH2- CH3- CH 4-crotonyl-1-piperazinyl- 31 EXAMPLE LXXVII The 2,4 disubstituted 6,7 dimethoxyquinazolines of Table XXVI are prepared according to the procedure of Examples XL, XLII and LXXX by substituting the ap- 5 propriate amine.

EXAMPLE LXXVIII The biological activity of the compounds of this invention, particularly in regard to their elfectiveness in reducing blood pressure in hypertensive subjects, is illustrated by the following tests on renal hypertensive dogs. The compounds were administered onally in capsule form. The effective dose level was that which lowered the blood pressure from 180/100 to 160/100 mm. Hg. The activity of the compounds is shown in Table XXVH.

TABLE XXVII.-HYPOTENSIVE ACTIVITY EXAMPLE LXXIX 2-furfurylamino-4-amino-6,7-dimethoxyquinazoline This compound is prepared according to the procedure of Example XXXVII by substituting alpha furfuryl amine for diethylamine. The product melts at 154-156" C. after recrystallization from ethyl acetate. The dihydrochloride melts at 258260 C.

In a similar manner, 2-(N-methylfurfurylamino)-4- amino-6,7-dimethoxyquinazoline is prepared. This compound melts at 270-274 C. after recrystallization from ethanol. The dihydrochloride melts at 275-276 C.

32 EXAMPLE LXXX The compounds of Table XXVIII are prepared by the procedure of Example XXXVII. Substituting the appropnate amine for diethylamine.

TABLE XXVIII EXAMPLE LXXXI The compounds of Table XXIX are prepared according to the procedures of Examples XL, .XLII, LXXIX and LXXX.

EXAMPLE LXXXII The compounds of Table XXX are prepared according to the procedures of Examples XXII, XXX, XXIX, and LXXXI.

R1 N N CHaH -z CHaO -N 2 CHBO N orno N I l Z R: R4

Rr(Ra) 1( 4) Z 2-turluryl H morpholino 2-thenyl H piperazino (2 turyl)ethyl H morpholino (2-thienyl)ethyl H phenyl I Z-Iurturyl H 4-phenylp1per1di0no EXAMPLE LXXXIII The compounds of Table XXXI are prepared by the procedures of Examples LXXII and LVII substituting the chloride indicated.

34 EXAMPLE LXXXIV 2-chloro-4-(Z-hydroxyethylamino)-6,7-dimethoxyquinazoline To ml. of tetrahydrofuran was added 7.75 grams 2,4-dichloro-6,7-dimethoxyquinazoline. To the stirred solution was added at room temperature, 5.38 ml. of 2- aminoethanol. The resulting suspension was stirred for 2 hours at room temperature and filtered to give 9.6 grams of the hydrochloride salt of 2-ch1oro-4-(2-hydroxyetliylamino -6,7 -dimethoxyquinazoline, M.P. 210-2-13 C The free base was prepared by suspending the hydrochloride in an aqueous solution of *sodium bicarbonate for 1 hour. The product,'7.25 grams (85.3% of theory) melted 249-251 C.

EXAMPLE LXXXV 2- [4- Z-furoyl -piperazinl-yl] -4- (2-hydroxyethylamino) -6,7-dimethoxyquinazoline 2- [4- (Z-furoyl) l--piperazinyl] -4-diacety1amino- 6,7-dimethoxyquinazoline A suspension of 9.12 grams (23.8 mmoles) of 2-[4- (2 furoyl) l-piperazinyl]-4-amino-6,7-dimethoxyquinazoline, ml. of pyridine and 175 ml. (189 grams, 1.848 moles) of acetic anhydride was heated on a stream cone to give a solution. The solution was stirred at room temperature for 16 hours and concentrated in vacuo to a crystalline residue. Recrystallization from ethyl alcoholwater gave 8.3 grams (78% of theory) of product, M.P. 230-233" C.

Analysis.-For C H O N (467.47). Calcd. (percent): C, 59.09; H, 5.39; N, 14.98.,Found (percent): C, 59.26; H, 5.49; N, 15.10.

EXAMPLE LXXXVII Z-diethylamino-4-acetamino-6,7-dimethoxyquinazoline To a solution of 3.2 grams 2 -diethylamino-4-amino- 6,7-dimethoxyquinazoline in 25 ml. pyridine was added 25 ml. (0.264 mole) of acetic anhydride. The mixture was stirred at room temperature for 2 hours and concentrated in vacuo to a crystalline residue. Recrystallization from ethyl alcohol-water gave 3.0 grams (82% of theory) of the pure product, M.P. 237-239 C.

Analysis.For C H O N (318.37). Calcd. (percent): C, 60.36; H, 6.97; N, 17.60. Found (percent): C, 60.71; H, 6.82; N, 17.70.

EXAMPLE LXXXVIII 2-diethylamino-4-[ (3-diethylamino propyl) amino] 6,7-dimethoxyquinazoline To a suspension of 6.0 grams 2-diethy1amino-4-chloro- 6,7-dimethoxyquinazo1ine hydrochloride in 50 ml. tetrahydrofuran was added 5.62 grams B-dimethylaminopropylamine. The resulting mixture was refluxed for 48 hours. The solution was concentrated to.an oil in vacuo. Crystallization from methyl alcohol water gave 3.7 grams (51.5% of theory) of product, M.P. 107-109 C.

35 (percent): C, 63.29; H, 9.06; N, 17.57. Found (percent): C, 63.28; H, 8.94; N, 17.29.

EXAMPLE LXXXIX 2-[4-(4-phenyl-4 -carboxylic acid ethyl ester)-1-piperidino]-4-amino-6,7-dimethoxyquinazoline This compound is prepared by the procedure of Example XXXVII by replacing diethylamine with 4-phenyl- 4-carbethoxypiperidine.

The methyl, propyl, butyl, pentyl and hexyl carboxylic acid esters of 2-[4 -(4-phenyl-4-carboxylic acid)-1-piperidino] 4 amino-6,7-dimethoxyquinazoline are prepared by the same procedure.

EXAMPLE XCI The biological activity of the compounds of Table XXXIII was tested according to the procedure of Example LXXVIII.

EXAMPLE XCII The 2,4 disubstituted 6,7 dimethoxyquinazolines in Table XXXIV were given orally to dogs at the levels shown. The resulting decrease in blood pressure is indicated.

TABLE XXXIV Compound N 01130 I-R CH O- I NH;

Blood Pressure Lowering, Dose, R mm. Hg mgJkg.

4-(3-ehlorophenyl)-1-piperazinyl 25 1. '25 4-(2-hydroxyethyl)-1-pipdrazlnyl 20 10. 4-(3-hydroxypropyD-1-piperazinyl 20 10. O 4-(2-thenoyl)-1-pipemzinyl 22 1. 25 2-morpholinoethylamino 10. 0

N omo- I -R 4 N CHaO- H OH;

Diethylamino 40 10 4-benzoyl-1-piperazinyl 30 1. 25 4-allyl-l-piperazinyl 1.

N cmo l l-R N CHaO- NHCH2CH20H 4 -turoyl-1-piperazinyl 25. 1

36 EXAMPLE xcm The biological activity of the compounds of Table XXXV was tested according to the procedure of Example LXXVIII.

TABLE XXXV Compound (311 0 I |-R cn ol NH;

Minimum effective R conc. (mg/kg.)

Azacyclooctyl 10.0

Azacyclohexyl 10.0

4-methylpiperidin0 10.0

4-n-propylpiperidino 0.31

4i-benzylpiperidino 0.31

4-phenylpiperidino 1.25

Morpholino 10.0

Cyclopropylamino 1.25

Benzylamino 10.0

4-butanoyl-l-piperazinyl 0.31

4-phenyl-1-piperazinyl 1.25

4-benzyl-l-piperazinyl 10.0

4-(3-chlorobenzoyl)-1-piperazinyl 10.0

4-(2-chlorobenzoyl)-1-piperazinyl 10.0

4-(3-methylbenzoyl)-l-piperazinyl 1.25

4-(3,4,5-trimethoxybenzoyl)-1-piperazinyl 10.0

4-(3-trifiuoromethylbenzoyl)-1-piperazinyl 10.0

What is claimed is:

1. A compound selected from the group consisting of those having the formula:

R1 R5 N N N R3 R4 where R R R and R are each selected from alkenyl having 3 to 5 carbon atoms, hydroxyalkyl having from 2 to 5 carbon atoms, phenyl, benzyl, phenylethyl, Z-furfuryl, 2,2,2-trifluoroethyl and cycloalkyl where alkyl has from 3 to 8 carbon atoms;

R and R are each selected from hydrogen and alkoxy having from 1 to 3 carbon atoms, at least one of R and R being alkoxy; and the acid addition salts thereof.

References Cited UNITED STATES PATENTS 3,511,836 5/1970 Hess 260251 Q 3,517,005 6/1970 Cronin et a1 260-256.4 Q

R. J. GALLAGHER, Assistant Examiner U.S. Cl. X.R. 260--256.5 R

UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3 635 979 I at January 18 1972 Inventor) Hans-Jurgen E. Hes s It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Col. 1, lines 9 and 27 "August 6, 1965" (two occurrences) should read --July 6, l965-.

Signed and Scaled this Twenty-fourth D a y Of April 1984 [SEAL] Attest:

GERALD J. MOSSINGHOFF A ttesting Officer Commissioner of Parents and Trademarks

Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3853873 *Jan 17, 1973Dec 10, 1974Parke Davis & Co2,4-diamino quinazoline derivatives
US3920636 *Oct 29, 1973Nov 18, 1975Eisai Co LtdQuinazoline compounds
US3960861 *Sep 5, 1973Jun 1, 1976Pfizer Inc.2 (OR 4) Amino 4 (or 2) N-hetero quinazolines
US3980650 *May 20, 1974Sep 14, 1976N.V. Koninklijke Pharmaceutische Fabrieken V/H Brocades-Stheeman En Pharmacia4-Amino-pyrimidine derivatives
US4044136 *Mar 3, 1976Aug 23, 1977Pfizer Inc.Aminoquinazoline therapeutic agents
US4092315 *Mar 1, 1976May 30, 1978Pfizer Inc.Novel crystalline forms of prazosin hydrochloride
US4101548 *Feb 22, 1977Jul 18, 1978Bristol-Myers Company1,2,3-Thiadiazole amides
US4171363 *May 17, 1978Oct 16, 1979Bristol-Myers Company1,2,3-Thiadiazole process
US4255429 *Jan 28, 1980Mar 10, 1981Ciba-Geigy CorporationN-Quinazolinylpiperidinyl-lactams
US4309541 *Apr 9, 1980Jan 5, 1982Ciba-Geigy CorporationPiperidinyl-lactams
US4315007 *Dec 10, 1979Feb 9, 1982Synthelabo4-Amino-6,7-dimethoxyquinazol-2-yl alkylenediamines
US4341893 *May 9, 1977Jul 27, 1982SynthelaboQuinazoline derivatives
US4352928 *Jun 16, 1980Oct 5, 1982Mitsubishi Yuka Pharmaceutical Co., Ltd.5,6-Alkylenepyrimidine derivative
US4440769 *Feb 11, 1983Apr 3, 1984Abbott Laboratories2-(4-Phenylalkanoylpiperazin-1-yl) quinazoline compounds, pharmaceutical compositions and method of producing α1 antagonistic activity
US4540696 *Feb 3, 1983Sep 10, 1985Sanofi S.A.1-Piperazinyl 4-phenylquinazoline compounds having antidepressant properties and drugs containing same
US4607034 *Oct 21, 1980Aug 19, 1986Mitsubishi Yuka Pharmaceutical Co., Ltd.Quinazoline derivatives and pharmaceutical composition thereof
US4639453 *Dec 7, 1984Jan 27, 1987Beiersdorf AktiengesellschaftSubstituted 1-(4-amino-6,7-dialkoxyquinazolinyl)-4 cyclohexenyl derivatives of piperazine and homopiperazine, processes for their preparation and their use, formulations containing these compounds and intermediates
US5064833 *May 8, 1990Nov 12, 1991Smithkline Beecham Intercredit B.V.Substituted quinazoline derivatives for use in gastrointestinal diseases
US5444062 *Oct 10, 1991Aug 22, 1995Pfizer Inc.Quinazolines derivatives for enhancing antitumor activity
US5534518 *Jun 28, 1994Jul 9, 1996Fmc CorporationInsecticidal substituted-2,4-diaminoquinazolines
US5576322 *Sep 30, 1992Nov 19, 1996Eisai Co., Ltd.Anti-ischemic 2,4-diaminoquinazolines
US5798362 *Mar 17, 1995Aug 25, 1998Recordati S.A. Chemical And Pharmaceutical CompanyQuinazolinyl-amino derivatives having α-antagonist activity
US5801180 *Jul 31, 1997Sep 1, 1998Eisai Co., Ltd.Quinazoline derivatives
US5874579 *May 1, 1996Feb 23, 1999Fmc CorporationInsecticidal substituted-2.4-diaminoquinazolines related applications
DE3015676A1 *Apr 23, 1980Nov 13, 1980PfizerNeue piperazinochinazolin-derivate, verfahren zu ihrer herstellung und solche derivate enthaltende arzneimittel
EP0053047A1 *Nov 26, 1981Jun 2, 1982Sankyo Company LimitedAcylaminoquinazoline derivatives, a process for their preparation and a pharmaceutical composition containing them
EP0322133A1 *Dec 2, 1988Jun 28, 1989SmithKline Beecham Intercredit B.V.Quinazoline derivatives
EP0404322B1 *May 9, 1990Sep 22, 1993Smithkline Beecham Intercredit B.V.Quinazoline derivatives
WO1989005297A1 *Dec 2, 1988Jun 15, 1989Smithkline Beckman Intercredit B.V.Compounds
WO1990003695A2 *Sep 26, 1989Apr 5, 1990SIEMENS AKTIENGESELLSCHAFT öSTERREICHProcess and device for converting the scanning signal of an analog input signal
WO1990003695A3 *Sep 26, 1989Sep 7, 1990Siemens Ag OesterreichProcess and device for converting the scanning signal of an analog input signal
WO1994018980A1 *Feb 17, 1994Sep 1, 1994Fmc CorporationInsecticidal substituted-2,4-diaminoquinazolines
WO1995025726A1 *Mar 17, 1995Sep 28, 1995Recordati S.A. Chemical And Pharmaceutical CompanyQUINAZOLINYL-AMINO DERIVATIVES HAVING α-ANTAGONIST ACTIVITY
WO1997020820A1 *Nov 18, 1996Jun 12, 1997Novartis AgHeteroaryl compounds
Classifications
U.S. Classification544/291, 544/249, 540/600, 544/292, 544/287
International ClassificationC07D239/95, C07D405/14, A61K31/505
Cooperative ClassificationC07D239/95, C07D405/14, Y10S514/929, A61K31/505
European ClassificationC07D405/14, A61K31/505, C07D239/95
Legal Events
DateCodeEventDescription
Apr 24, 1984CCCertificate of correction